Pharmaron vs Wacker Biotech: CDMO Comparison
How does Pharmaron compare to Wacker Biotech?
As of Nov 2026, Pharmaron: 5 FDA inspections (including 4 NAI, 1 VAI and 0 OAI), 1 EMA/MHRA GMP certificate. Signal Score 86.9. Wacker Biotech: 1 FDA inspection (including 0 NAI, 1 VAI and 0 OAI), 13 EMA/MHRA GMP certificates. Signal Score 82.9. Counts are the established FDA, EMA and MHRA records on each profile. CDMOs cannot pay to change a score.
Side-by-side comparison of Pharmaron and Wacker Biotech on independent FDA inspections, EMA and MHRA GMP certificates, clinical-program activity, and CDMO Signal Score. Data sourced from FDA, EMA EudraGMDP, MHRA GMDP, and ClinicalTrials.gov.
Key differences
- Pharmaron has more FDA inspections on record (5 vs 1) — a deeper regulatory paper trail.
- Both maintain clean enforcement records — no FDA OAI classifications or warning letters on file for either CDMO.
- Wacker Biotech holds 13 active EMA GMP certificates; Pharmaron does not appear in EudraGMDP.
- Pharmaron maintains 1 MHRA / UK GMP certificate; Wacker Biotech does not.
Across the cross-modality scorecard, Pharmaron carries the higher composite Signal Score — but the right choice depends on the specific modality, phase, and geography of the program.
Frequently asked: Pharmaron vs Wacker Biotech
How does Pharmaron compare to Wacker Biotech?
On CDMO Signal's composite Signal Score, Pharmaron is 87/100 and Wacker Biotech is 83/100; Pharmaron has 5 FDA inspections on record vs 1 for Wacker Biotech; European coverage is 1 active EMA+MHRA certificate for Pharmaron vs 13 for Wacker Biotech. Both are tracked in the CDMO Signal directory. The scorecard above breaks down every metric side by side — use it alongside each CDMO's individual profile for the full regulatory and clinical footprint.
Which has the stronger FDA inspection record, Pharmaron or Wacker Biotech?
Both Pharmaron and Wacker Biotech maintain clean enforcement records on file — no FDA warning letters and no OAI classifications. Pharmaron has 5 FDA inspections on record; Wacker Biotech has 1.
How do Pharmaron and Wacker Biotech compare on European GMP coverage?
Pharmaron holds 0 active EMA GMP certificates and 1 MHRA / UK certificate. Wacker Biotech holds 13 active EMA GMP certificates and 0 MHRA / UK certificates. Use these counts as a proxy for the breadth of each CDMO's European regulatory footprint.
What does the Signal Score gap mean in practice?
Pharmaron carries a Signal Score of 87/100 and Wacker Biotech carries 83/100 — essentially tied for Pharmaron. The Signal Score combines quality (FDA inspections + EMA/MHRA GMP), operational performance, financial stability, and capacity intelligence. CDMOs cannot pay to influence their score.
Use the free AI matchmaker to weigh both against your specific requirements — capacity, modality, regulatory record, geography — and surface other qualified options.
Find & compare CDMOs →